

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 02877)

ANNOUNCEMENT OF TURNOVER INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2015

The Company is pleased to announce its financial information of turnover, which has not been reviewed by its auditors, for the three months ended 31 March 2015.

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce the preliminary financial information of turnover of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2015 based on its management accounts which have not been reviewed by the auditors.

Total turnover of the Group, which has not been reviewed by the auditors, for the three months ended 31 March 2015 increased by approximately 1.5% as compared with the same period of 2014 to approximately RMB546 million, and in particular:

- Turnover for the three months ended 31 March 2015 of injection products increased by approximately 3.8% as compared to the same period of 2014 to approximately RMB304 million;
- Turnover for the three months ended 31 March 2015 of soft capsule products decreased by approximately 15.20% as compared to the same period of 2014 to approximately RMB116 million;
- Turnover for the three months ended 31 March 2015 of granule products increased by approximately 11.7% as compared to the same period of 2014 to approximately RMB104 million; and
- Products in other forms recorded turnover of approximately RMB22 million for the three months ended 31 March 2015.

In terms of product mix, injection products, soft capsule products and granule products accounted for approximately 55.7%, 21.3% and 18.9% of the total turnover respectively, all of which have not been reviewed by the auditors, for the three months of 2015.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 24 April 2015

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin, Ms. Lee Ching Ton Brandelyn, Dr. Wang Zheng Pin and Mr. Chen Zhong; and the independent non-executive Directors are Mr. Hung Randy King Kuen, Ms. Cheng Li and Mr. Sun Liutai.